Skip to Main Content

Alfred Chung



Dr. Alfred Chung is a hematologist-oncologist who cares for patients with blood cancers, including leukemias, lymphomas and myelomas. He sees patients who are in the hospital for treatment, including those who need a bone marrow transplant and those receiving chemotherapy or cellular therapies to bolster the immune system.

Chung's research centers on the study and development of new therapies for plasma cell disorders, including multiple myeloma and amyloidosis (buildup of an abnormal protein called amyloid in the organs). One specific area of study is light chain amyloidosis, in which the dysfunction of certain antibody-producing cells results in abnormal protein fibers in the organs. Chung is looking specifically at targeted therapies to treat this type of amyloidosis as well as novel therapeutic strategies in the treatment of multiple myeloma.

After earning a bachelor's degree in chemical engineering at the University of Michigan, Chung earned a medical degree at Northwestern University Feinberg School of Medicine. At Stanford Medicine, he completed a residency in internal medicine, followed by a fellowship in hematology and oncology.

Chung is a member of the American Society of Clinical Oncology, American Society of Hematology and Association of Northern California Oncologists.

  • Education

    Feinberg School of Medicine, MD, 2014

  • Residencies

    Stanford Medicine, Internal Medicine, 2017

  • Fellowships

    Stanford Medicine, Hematology and Oncology, 2020

  • Academic Title

    Assistant Professor

My reviews


Overall Experience
133 Ratings
Explained things in a way that was easy to understand
133 Ratings
Did the doctor pay attention to your concerns
132 Ratings
Gave easy to understand instructions about taking care of health problems or concerns
130 Ratings
Knew the important information about your medical history
133 Ratings
The provider showed respect for what you had to say
131 Ratings
The provider spent enough time with me
132 Ratings
Each patient has a unique story and perspective. I am committed to providing compassionate medical care to people of all backgrounds.

Where I see patients (1)

    Decorative Caduceus

    Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-...

    The International Myeloma Working Group (IMWG) uniform response criteria will be used to assess disease response and progression. The response rate is defined as the proportion of patients achieving a partial response (PR), very g...


    Decorative Caduceus

    Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refract...

    ORR is defined as stringent complete response (sCR) + complete response (CR) + very good partial response + partial response (PR) as best response using International Myeloma Working Group (IMWG) Uniform Response Criteria for all ...